Life Sciences
Asia-Pacific Guide 2024 : Asia-Pacific Region
Band 2
Email address
[email protected]Contact number
+86 10 5909 3399Chambers Review
Thanks to its global network, Morrison Foerster is well placed to provide IP and corporate support to biotech companies and leading investors on joint ventures, funding, patent litigation and enforcement, and licensing issues in the life sciences sphere. It is also noted for core technology expertise within the sector and an impressive transactional capability across the Asia-Pacific region. The firm is particularly well versed in negotiating the licensing and development of pharmaceutical products as part of joint venture arrangements. The team regularly coordinates venture capital and corporate transactions with a network of colleagues based in offices across the USA.
Gordon Milner and Thomas Chou in Hong Kong, and Sun Chuan in Shanghai, are key contacts for the China life sciences practice. The key contact for the firm's life sciences practice in Japan is Gary Smith.
Work Highlights
- Morrison Foerster advised Tate & Lyle on its USD237 million acquisition of a prebiotic dietary fibre company, Quantum Hi-Tech (Guangdong) Biological.
- Morrison Foerster's cross-office trial team, co-led by Tokyo and US offices, secured a USD775 million patent litigation settlement for Chugai Pharmaceutical in relation to Alexion Pharmaceuticals’ sales of an anti-complement antibody product, Ultomiris.
Strengths
Provided by Chambers
"Morrison Foerster's team has deep knowledge, and it knows the company and stakeholders well."
"The team is experienced and can provide useful advice with a good understanding of the commercial channels in the pharmaceutical industry."
"Morrison Foerster's team has deep knowledge, and it knows the company and stakeholders well."
"The team is experienced and can provide useful advice with a good understanding of the commercial channels in the pharmaceutical industry."